PA
PBYI icon

Perceptive Advisors’s Puma Biotechnology PBYI Stock Holding History

Perceptive Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-564,579
Closed -$27.7M – 128
2018
Q2 		$27.7M Buy
564,579
+122,400
+28% +$7.09M 0.73% 37
2018
Q1 		$30.1M Sell
442,179
-261,641
-37% -$19.6M 0.84% 29
2017
Q4 		$69.6M Sell
703,820
-220,000
-24% -$24.6M 2.31% 9
2017
Q3 		$111M Buy
923,820
+190,500
+26% +$17.7M 4.23% 6
2017
Q2 		$64.1M Buy
+733,320
New +$41M 3.23% 7
2017
Q1 		– Sell
-7,344
Closed -$225K – 191
2016
Q4 		$225K Hold
7,344
– – 0.02% 140
2016
Q3 		$492K Buy
+7,344
New +$371K 0.03% 129
2014
Q4 		– Sell
-11,000
Closed -$2.62M – 164
2014
Q3 		$2.62M Buy
+11,000
New +$2.26M 0.27% 63
2014
Q2 		– Sell
-735
Closed -$76K – 134
2014
Q1 		$76K Hold
735
– – 0.01% 124
2013
Q4 		$76K Buy
+735
New +$43.1K 0.01% 102

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Perceptive Advisors's PBYI Position: Q3 2018 in Review

Perceptive Advisors sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 564,579 shares — an estimated $27.7M sold.

Perceptive Advisors first reported a position in PBYI in Q4 2013 and held it in 10 quarters. The position peaked at $111M in Q3 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Perceptive Advisors reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 564,579 Puma Biotechnology shares in Q3 2018, an estimated $27.7M.
  • Perceptive Advisors first reported a position in Puma Biotechnology in Q4 2013 and held it in 10 quarters.
  • Perceptive Advisors's Puma Biotechnology position peaked at $111M in Q3 2017.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.